Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.
Susan O’Brien(University of California, Irvine), Jennifer R. Brown(Dana-Farber Cancer Institute), Eric Hedrick(Florida Hospital Cancer Institute), Jonathan W. Friedberg(University of Rochester), Paul M. Barr(University of Rochester Medical Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Jacqueline C. Barrientos(Mount Sinai Medical Center), Ian W. Flinn(Tennessee Oncology), Danelle F. James(Pharmacyclics (United States)), Tasheda Navarro(Pharmacyclics (United States))
Cited by 36
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k